According to the National Poll on Healthy Aging, nearly 60% of older adults with obesity were interested in a weight management drug. Over three-fourths of surveyed seniors thought Medicare should ...

(MENAFN- GlobeNewsWire - Nasdaq) - Participants in the combined treatment group lost significantly more weight at 3, 6, and 12 months and were more likely to lose 5%, 10%, or >15% of their body weight ...

The FDA is requesting that drugmakers remove suicidal ideation and behavior warnings from the labeling of three GLP-1 receptor agonists — Saxenda (liraglutide), Wegovy (semaglutide) and Zepbound ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA has requested mention of risk for suicidal ...

Regulator asks drugmakers to remove warnings of suicidal thoughts from GLP-1 drugs' labels FDA finds no link between GLP-1 drugs and suicidal thoughts Novo Nordisk and Eli Lilly welcome FDA's ...

The U.S. health regulator on Tuesday asked drugmakers to remove label warnings about a potential risk of suicidal thoughts from widely used GLP-1 weight-loss drugs, including Novo Nordisk's Wegovy and ...

CAMPBELL, Calif. and HONOLULU, Jan. 07, 2026 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on ...

Most weight loss drugs are FDA-approved for people with obesity or overweight with a weight-related health condition. A healthcare provider can help you find the best weight loss medication for you.

Globally, more than 1 billion people currently live with obesity. The World Health Organization on Monday released new guidance on GLP-1 medications for adults with obesity, recommending their ...